NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Yale University
Shanghai Junshi Bioscience Co., Ltd.
Pfizer
N.N. Petrov National Medical Research Center of Oncology
Cambridge University Hospitals NHS Foundation Trust